We can’t show the full text here under this license. Use the link below to read it at the source.
Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety
Glucagon-like peptide-1 receptor agonists and their benefits and safety in heart attack and artery disease: a detailed analysis of treatment effectiveness
AI simplified
Abstract
GLP-1 receptor agonists reduced the risk of myocardial infarction by 14%, with a of 207 to prevent one event.
- Among 109,846 patients across 25 studies, GLP-1 receptor agonists demonstrated a significant reduction in .
- The risk of cardiovascular mortality was reduced by 13% with a numbers needed to treat of 170.
- A 12% reduction in stroke risk was observed, with a numbers needed to treat of 335.
- Higher body mass index was linked to a greater reduction in myocardial infarction risk among GLP-1 receptor agonist users.
- Gastrointestinal side effects were commonly reported, with a numbers needed to harm of 9.
AI simplified
Key numbers
207
for Total MI Reduction
to prevent one event of total myocardial infarction over 3.48 years
170
for Cardiovascular Mortality Reduction
to prevent one event of cardiovascular mortality
67
for Reduction
to prevent one event of